Protein therapeutics

Any protein therapeutic may induce an immune reaction after in vivo administration leading to the formation of anti-drug antibodies and finally the elimination of the therapeutic protein. As this represents a major reason for reduced efficacy and therefore sales of antibody therapeutics, pharmaceutical companies typically screen for therapeutic proteins that are low immunogenic.

One of Alithea’s tools is the profiling of peptides from drug products presented on antigen-presenting cells by mass spectrometry. Alithea has the capacity to purify HLA class II-presented peptides through the same workflow as for the identification of HLA class I peptides and can thereby support such studies.

If you are interested in protein therepeutics, please reach out to us below